1. successfully constructed and prepared CEA-rA for the first time in China, and established the quality standard of biological activity determination, which confirmed the related research on the mechanism of CEA's obvious prevention and treatment of mice tumors.
2. DC and CIK cells were successfully prepared from umbilical cord blood mononuclear cells. Firstly, CIK is induced by DC carrying CEA-rA at home and abroad. The effector cells CEA-rA+DC+CIK with specific killing effect on CEA-positive tumors were prepared. Cytological experiments showed that compared with CIK cells, the killing activity of effector cells on CEA-positive tumor cells increased by 89%, and animal experiments showed that the growth and yield of CEA-positive transplanted tumor in nude mice increased by 100% compared with cells.
3. For the first time in China, CIK cell infusion and CEA-rA subcutaneous inoculation were used to treat 5 patients with advanced CEA-positive tumors, which achieved ideal results and no adverse reactions were found. This project took the lead in constructing and preparing CEA-rA in China, and it was initially applied in clinic, and achieved ideal results. First of all, a series of international studies have been carried out on the therapeutic effect of CEA-rA+DC+CIK effector cells on CEA-positive tumors. It has achieved important phased results, filled the domestic gap and reached the international advanced and domestic leading level. In 2008, the project passed the appraisal organized by Guangdong Science and Technology Department, and declared the invention patent in China National Intellectual Property Administration. It is the first time to treat severe systemic lupus erythematosus with biotherapy in China, and it has achieved unexpected good results.